• Landmark paper on Viravaxx’ rhinovirus diagnostic tool published in Nature Communications

    Viravaxx announced today that a Landmark paper describing the utility of its multiplexed diagnostic chip for analysis of the immune response to a rhinovirus infection in children has been published in the high impact Journal Nature Communications. The following is a comment in the “behind the paper” blog in Nature Community Microbiology: “Major factors triggering asthma attacks | read more »

    read more »

  • Viravaxx closes Series A investment round

    Vienna, Jan. 17, 2017 Viravaxx AG, an emerging biopharmaceutical company focussed on the development of antiviral vaccines for difficult to treat virus infections as well as diagnostic products for the detailed analysis of the immunological response to virus infections, announced today the closing of private financing round in the amount of €4.22 million. Participating in | read more »

    read more »